Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of the American Pharmacists Association

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1331/JAPhA.2008.07007PMID 18595825
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Untitled Page

  2012cited by this paper
• Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.

  2007cited by this paper
• Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders.

  2007cited by this paper
• Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals.

  2006cited by this paper
• Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.

  2006cited by this paper
• Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.

  2006cited by this paper
• Undiagnosed hyperglycemia in patients treated with atypical antipsychotics.

  2005cited by this paper
• Switching Between Second-Generation Antipsychotics

  2005cited by this paper
• Challenges in the management of bipolar depression.

  2005cited by this paper
• A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study.

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• A crossover study on lipid and weight changes associated with olanzapine and risperidone

  2005cited by this paper
• Metabolic issues and cardiovascular disease in patients with psychiatric disorders.

  2005cited by this paper
• Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

  2005cited by this paper
• [The metabolic syndrome and mental illness: relevance, risk factors and practical consequences].

  2005cited by this paper
• Second-Generation (Atypical) Antipsychotics and Metabolic Effects

  2005cited by this paper
• Schizophrenia and comorbid metabolic disorders.

  2005cited by this paper
• [The metabolic syndrome and mental illness: relevance, risk factors and practical consequences].

  2005cited by this paper
• The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: Practice Patterns and Knowledge of Psychiatrists

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes.

  2004cited by this paper
• Physical health monitoring of patients with schizophrenia.

  2004cited by this paper
• Atypical antipsychotics and glucose dysregulation: a systematic review.

  2004cited by this paper
• Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

  2003cited by this paper
• Obesity, Diabetes, and the Metabolic Syndrome: New Challenges in Antipsychotic Drug Therapy

  2003cited by this paper
• Use of general medical services by VA patients with psychiatric disorders.

  2002cited by this paper
• Outcomes assessment of clinical pharmacy services in a psychiatric inpatient setting.

  2001cited by this paper
• The Impact of Clinical Pharmacists on Psychiatric Patients

  1996cited by this paper
• Psychopathy, schizophrenia, alcohol abuse, and violent recidivism.

  1995cited by this paper
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

  1993cited by this paper

• Poor Medication Compliance in Schizophrenia from an Illness and Treatment Perspective

  2017cites this paper
• Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home

  2016influential citation
• Would Better Policing of Metabolic Status Help You Avoid Medicolegal Worries

  2016cites this paper
• Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System

  2015cites this paper
• Community Adherence to Schizophrenia Treatment and Safety Monitoring Guidelines

  2014cites this paper
• Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation

  2013cites this paper
• Metabolic Monitoring of Patients Prescribed Second-Generation Antipsychotics

  2013cites this paper
• Monitoring veterans for metabolic side effects when prescribing antipsychotics.

  2013cites this paper
• Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting.

  2012cites this paper
• Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication.

  2012cites this paper
• An update on lipid profile screening in second-generation antipsychotic users in the USA

  2012cites this paper
• The Delivery System Design of a Community Mental Health Center and Provision of Quality: Cardiometabolic Screening for Persons with a Severe Mental Illness Prescribed Atypical Antipsychotic Medication

  2012cites this paper
• Small area variation and geographic and patient‐specific determinants of metabolic testing in antipsychotic users

  2011cites this paper
• Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia

  2011cites this paper
• Predicting implementation from organizational readiness for change: a study protocol

  2011cites this paper
• Efectos adversos metabólicos y endocrinos de los antipsicóticos de segunda generación en niños y adolescentes: una revisión sistemática de ensayos aleatorizados, controlados con placebo y guías de práctica clínica

  2011cites this paper
• Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation

  2011cites this paper
• Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

  2011cites this paper
• Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices

  2011influential citation
• Lipid profile screening in second-generation antipsychotic users: the gap between policy and practice

  2010cites this paper
• Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

  2010cites this paper
• Editorial for Nordic Journal of Psychiatry

  2010cites this paper
• Assessment of Monitoring for Glucose and Lipid Dysregulation in Adult Medi-Cal Patients Newly Started on Antipsychotics

  2010cites this paper
• Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics.

  2009cites this paper
• Prevalence and correlates of glucose monitoring in Chinese psychiatric patients on antipsychotics.

  2009cites this paper